论文部分内容阅读
目的:探讨CVC、PICC及PORT用于恶性肿瘤化疗患者疗效及安全性差异。方法:选取象山县第一人民医院2015年2月-2017年2月恶性肿瘤化疗患者共150例,随机分为A组、B组及C组,每组各50例;其中A组采用CVC中心静脉置管,B组采用PICC中心静脉置管,C组则采用PORT中心静脉置管;比较3组患者置管症状影响评分、生命质量测定量表评分(QLICP)、导管相关并发症发生率及患者满意度等。结果:A、B及C组患者置管症状影响评分分别为(14.72±2.21)分,(14.40±2.16)分,(14.57±2.21)分;三组患者置管症状影响评分比较差异无显著性(P>0.05);A组躯体功能、心理功能、症状与不良反应及社会功能评分分别为(21.82±2.04)分,(41.34±5.16)分,(29.86±3.25)分,(36.21±4.60)分;B组躯体功能、心理功能、症状与不良反应及社会功能评分分别为(25.31±3.67)分,(44.70±7.33)分,(32.35±4.71)分,(40.94±6.17)分;C组躯体功能、心理功能、症状与不良反应及社会功能评分分别为(27.05±5.11)分,(48.29±9.84)分,(36.61±6.80)分,(44.15±7.95)分;C组患者QLICP评分者显著高于A、B组(P<0.05);A组、B组及C组导管相关并发症发生率分别为36.00%,18.00%,6.00%;C组患者导管相关并发症发生率显著低于A、B组(P<0.05);A组、B组及C组患者满意度分别为70.00%,84.00%,96.00%;C组患者临床满意度显著高于A、B组(P<0.05)。结论:PORT中心静脉置管用于恶性肿瘤化疗患者可有效减轻相关症状体征,改善日常生活质量,降低并发症发生风险,并有助于提高护理服务满意,价值优于CVC和PICC。
Objective: To investigate the efficacy and safety of CVC, PICC and PORT for malignant tumor chemotherapy. Methods: A total of 150 patients with malignant tumor chemotherapy in the First People’s Hospital of Xiangshan from February 2015 to February 2017 were randomly divided into A group, B group and C group, with 50 cases in each group. A group was treated with CVC center The patients in group B received PICC central venous catheterization while those in group C received PORT central venous catheterization. The catheterization symptom score, quality of life questionnaire (QLICP), incidence of catheter-related complications, Patient satisfaction and so on. Results: The scores of catheterization symptoms in group A, B and C were (14.72 ± 2.21), (14.40 ± 2.16) and (14.57 ± 2.21) points respectively. There was no significant difference between the three groups in catheter symptom scores (21.82 ± 2.04), (41.34 ± 5.16) points, (29.86 ± 3.25) points and (36.21 ± 4.60) points respectively in group A (P> 0.05). The score of physical function, psychological function, symptom and adverse reaction and social function in group A were (21.82 ± 2.04) (25.31 ± 3.67) points, (44.70 ± 7.33) points, (32.35 ± 4.71) points and (40.94 ± 6.17) points respectively in group B; The scores of somatic function, psychological function, symptoms and adverse reactions and social function in group B were significantly lower than those in group C (27.05 ± 5.11) points, (48.29 ± 9.84) points, (36.61 ± 6.80) points and (44.15 ± 7.95) points respectively. The QLICP scores in group C were significantly higher than those in group C (P <0.05). The incidences of catheter-related complications in group A, group B and group C were 36.00%, 18.00% and 6.00% respectively. The incidence of catheter-related complications in group C was significantly lower than that in group A A, B (P <0.05). The satisfaction of patients in group A, group B and group C was 70.00%, 84.00% and 96.00% respectively. The clinical satisfaction of group C was significantly higher than that of group A and B (P <0.05) . Conclusion: PORT central venous catheterization for patients with malignant tumor chemotherapy can effectively reduce the symptoms and signs, improve the quality of daily life, reduce the risk of complications, and help to improve the satisfaction of nursing services, the value is better than CVC and PICC.